Pizuglanstat (hydrate)

Pizuglanstat hydrate (Compound 3; TAS-205) is an orally active prostaglandin D synthase inhibitor with an IC50 of 76 nM for human hematopoietic prostaglandin D synthase. Pizuglanstat hydrate inhibits the synthesis of PGD2. Pizuglanstat hydrate improves experimental allergic rhinitis. Pizuglanstat hydrate can be used in the study of muscle regenerative diseases such as muscular dystrophy[1][2][3].

Product Specifications

CAS Number

[1584160-52-0]

Product Name Alternative

TAS-205

UNSPSC

12352005

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pizuglanstat-hydrate.html

Smiles

O=C(N1CCOCC1)C2CCN(C3=CC=C(NC(N4CCN(C(C5=CC=CN5C)=O)CC4)=O)C=C3)CC2.O

Molecular Formula

C27H38N6O5

Molecular Weight

526.63

References & Citations

[1]Aoyagi H, et al. Potential synergistic effects of novel hematopoietic prostaglandin D synthase inhibitor TAS-205 and different types of anti-allergic medicine on nasal obstruction in a Guinea pig model of experimental allergic rhinitis. Eur J Pharmacol. 2020 May 15;875:173030. |[2]Yoshihiro Urade, et al. Piperazine compound capable of inhibiting prostaglandin D synthase. United States. US8865714B2. 2010-03-08.|[3]Komaki H, et al. Early phase 2 trial of TAS-205 in patients with Duchenne muscular dystrophy. Ann Clin Transl Neurol. 2020 Feb;7 (2) :181-190.